1-7 of 7
Idit Sagiv Barfi, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

In Situ Vaccination with Cpg and Anti-OX40 Antibody: Preclinical Optimization for Clinical Translation

Idit Sagiv Barfi, PhD, Debra K. Czerwinski, BA, Tanaya Shree, MD PhD BA, Ronald Levy, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2943.
https://doi.org/10.1182/blood-2018-99-117872
Published: 2018
Journal Articles

Eradication of Systemic Lymphoma By Local Immunotherapy

Idit Sagiv Barfi, PhD, Debra K. Czerwinski, BA, Ronald Levy, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 113.
https://doi.org/10.1182/blood.V130.Suppl_1.113.113
Published: 2017
Journal Articles

Activity of a Sting and a TLR9 Agonist As an “in Situ Therapeutic Vaccination” Against Lymphomas

Adrienne Sallets, PhD, Idit Sagiv Barfi, PhD, Ron Levy, MD
Journal: Blood
Blood (2016) 128 (22): 48.
https://doi.org/10.1182/blood.V128.22.48.48
Published: 2016
Journal Articles

Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do Not Antagonize Rituximab-Dependent NK-Cell Mediated Cytotoxicity

Narendiran Rajasekaran, PhDMSc, Mohith Sadaram, BS, Jonathan Hebb, MD, Idit Sagiv-Barfi, PhD, Sid Ambulkar, Amanda Rajapaksa, Serena Chang, PhD, Cariad Chester, Erin Waller, Lai Wang, PhD, Brian Lannutti, PhD, Dave Johnson, Ron Levy, MD, Holbrook E Kohrt, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3118.
https://doi.org/10.1182/blood.V124.21.3118.3118
Published: 2014
Journal Articles

Combination Immunotherapy of Advanced Lymphoma with Oncolytic Vaccinia Virus and Checkpoint Inhibitor Following Local Tumor Irradiation

Boris Minev, MD, Holbrook Kohrt, MD, Mehmet Kilinc, PhD, Nanhai Chen, PhD, Audrey Feng, Maysam Pessian, Ulrike Geissinger, Erik Haefner, Desislava Tsoneva, Kliment Bozhilov, Idit Sagiv Barfi, PhD, Xing Zhao, Narendiran Rajasekaran, PhDMSc, Ronald Levy, MD, Aladar Szalay, PhD
Journal: Blood
Blood (2014) 124 (21): 4487.
https://doi.org/10.1182/blood.V124.21.4487.4487
Published: 2014
Journal Articles

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Sylvia Herter, PhD, Idit Sagiv-Barfi, PhD, Cariad Chester, Mohith Sadaram, BS, Jonathan Hebb, MD, Debra K Czerwinski, Narendiran Rajasekaran, PhDMSc, Marina Bacac, PhD, Pablo Umana, PhD, Ron Levy, MD, Christian Klein, PhD, Holbrook E Kohrt, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1765.
https://doi.org/10.1182/blood.V124.21.1765.1765
Published: 2014
Journal Articles

Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity

Holbrook E Kohrt, MD, PhD, Idit Sagiv-Barfi, PhD, Sarwish Rafiq, MS, Sarah E.M. Herman, Jonathan P Butchar, Ph.D., Carolyn Cheney, B.S, Xiaoli Zhang, PhD, MS, Joseph J. Buggy, PhD, Natarajan Muthusamy, DVM, Ph.D, Ronald Levy, MD, Amy J Johnson, PhD, John C. Byrd, MD
Journal: Blood
Blood (2013) 122 (21): 373.
https://doi.org/10.1182/blood.V122.21.373.373
Published: 2013